Royal Bank of Canada Cuts Aurinia Pharmaceuticals (NASDAQ:AUPH) Price Target to $18.00

Aurinia Pharmaceuticals (NASDAQ:AUPHGet Rating) (TSE:AUP) had its price target trimmed by Royal Bank of Canada from $22.00 to $18.00 in a research report report published on Friday morning, BayStreet.CA reports. The brokerage currently has an outperform rating on the biotechnology company’s stock.

A number of other brokerages have also commented on AUPH. StockNews.com raised Aurinia Pharmaceuticals from a sell rating to a hold rating in a report on Monday, May 23rd. Cantor Fitzgerald reissued an overweight rating on shares of Aurinia Pharmaceuticals in a report on Thursday, April 28th. Finally, HC Wainwright lowered their price objective on Aurinia Pharmaceuticals from $33.00 to $30.00 in a report on Wednesday, May 4th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Aurinia Pharmaceuticals presently has a consensus rating of Moderate Buy and an average price target of $24.80.

Aurinia Pharmaceuticals Price Performance

Shares of AUPH stock opened at $8.37 on Friday. Aurinia Pharmaceuticals has a fifty-two week low of $7.70 and a fifty-two week high of $33.97. The stock’s 50-day moving average is $10.63 and its two-hundred day moving average is $12.25. The firm has a market cap of $1.19 billion, a P/E ratio of -7.22 and a beta of 0.94.

Aurinia Pharmaceuticals (NASDAQ:AUPHGet Rating) (TSE:AUP) last issued its earnings results on Thursday, August 4th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.03). Aurinia Pharmaceuticals had a negative return on equity of 38.37% and a negative net margin of 178.32%. During the same period last year, the business earned ($0.37) earnings per share. As a group, research analysts expect that Aurinia Pharmaceuticals will post -0.7 EPS for the current year.

Institutional Trading of Aurinia Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in AUPH. Bellevue Group AG bought a new stake in Aurinia Pharmaceuticals during the 1st quarter valued at approximately $29,784,000. Renaissance Technologies LLC boosted its stake in Aurinia Pharmaceuticals by 262.7% during the 1st quarter. Renaissance Technologies LLC now owns 1,694,200 shares of the biotechnology company’s stock valued at $20,974,000 after purchasing an additional 1,227,129 shares during the period. Citigroup Inc. boosted its stake in Aurinia Pharmaceuticals by 7,641.6% during the 4th quarter. Citigroup Inc. now owns 768,195 shares of the biotechnology company’s stock valued at $17,569,000 after purchasing an additional 758,272 shares during the period. Kestra Private Wealth Services LLC bought a new stake in Aurinia Pharmaceuticals during the 1st quarter valued at approximately $7,204,000. Finally, Pictet Asset Management SA boosted its stake in Aurinia Pharmaceuticals by 42.6% during the 4th quarter. Pictet Asset Management SA now owns 1,449,624 shares of the biotechnology company’s stock valued at $33,153,000 after purchasing an additional 433,205 shares during the period. Institutional investors own 33.09% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

(Get Rating)

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.

Recommended Stories

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.